nach oben

Virchows Archiv

Erschienen in:

01.01.2020 | Review Article

What’s new in fibroblastic tumors?

verfasst von: Susan M. Armstrong, Elizabeth G. Demicco

Erschienen in: Virchows Archiv | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Over the last 10 years, a number of advances have been made in our understanding of fibroblastic and myofibroblastic tumors. The rapidly evolving field of molecular diagnostics has resulted in the recognition of new entities and better understanding of tumor pathogenesis, while careful clinicopathologic correlative analyses have led to improvements in modeling tumor behavior. This review will discuss new and emerging entities in fibroblastic neoplasia and provide updates on the pathogenesis, diagnosis, and prognostication of these diverse and challenging tumors.

Kao YC, Flucke U, Eijkelenboom A, Zhang L, Sung YS, Suurmeijer AJH, Antonescu CR (2018) Novel EWSR1-SMAD3 gene fusions in a group of acral fibroblastic spindle cell neoplasms. Am J Surg Pathol 42:522–528. https://doi.org/10.1097/PAS.0000000000001002CrossRefPubMedPubMedCentral

Michal M, Berry RS, Rubin BP, Kilpatrick SE, Agaimy A, Kazakov DV, Steiner P, Ptakova N, Martinek P, Hadravsky L, Michalova K, Szep Z, Michal M (2018) EWSR1-SMAD3-rearranged fibroblastic tumor: an emerging entity in an increasingly more complex group of fibroblastic/myofibroblastic neoplasms. Am J Surg Pathol 42:1325–1333. https://doi.org/10.1097/PAS.0000000000001109CrossRefPubMed

Carter JM, Weiss SW, Linos K, DiCaudo DJ, Folpe AL (2014) Superficial CD34-positive fibroblastic tumor: report of 18 cases of a distinctive low-grade mesenchymal neoplasm of intermediate (borderline) malignancy. Mod Pathol 27:294–302. https://doi.org/10.1038/modpathol.2013.139CrossRefPubMed

Lao IW, Yu L, Wang J (2017) Superficial CD34-positive fibroblastic tumour: a clinicopathological and immunohistochemical study of an additional series. Histopathology 70:394–401. https://doi.org/10.1111/his.13088CrossRefPubMed

Puls F, Pillay N, Fagman H, Palin-Masreliez A, Amary F, Hansson M, Kindblom LG, McCulloch TA, Meligonis G, Muc R, Rissler P, Sumathi VP, Tirabosco R, Hofvander J, Magnusson L, Nilsson J, Flanagan AM, Mertens F (2019) PRDM10-rearranged soft tissue tumor: a clinicopathologic study of 9 cases. Am J Surg Pathol 43:504–513. https://doi.org/10.1097/PAS.0000000000001207CrossRefPubMed

Michal M, Kazakov DV, Hadravsky L, Kinkor Z, Kuroda N, Michal M (2015) High-grade myxoinflammatory fibroblastic sarcoma: a report of 23 cases. Ann Diagn Pathol 19:157–163. https://doi.org/10.1016/j.anndiagpath.2015.03.012CrossRefPubMed

Marino-Enriquez A, Fletcher CD (2012) Angiofibroma of soft tissue: clinicopathologic characterization of a distinctive benign fibrovascular neoplasm in a series of 37 cases. Am J Surg Pathol 36:500–508. https://doi.org/10.1097/PAS.0b013e31823defbeCrossRefPubMed

Bekers EM, Groenen P, Verdijk MAJ, Raaijmakers-van Geloof WL, Roepman P, Vink R, Gilhuijs NDB, van Gorp JM, Bovee J, Creytens DH, Flanagan AM, Suurmeijer AJH, Mentzel T, Arbajian E, Flucke U (2017) Soft tissue angiofibroma: clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes Cancer 56:750–757. https://doi.org/10.1002/gcc.22478CrossRefPubMed

Yamada Y, Yamamoto H, Kohashi K, Ishii T, Iura K, Maekawa A, Bekki H, Otsuka H, Yamashita K, Tanaka H, Hiraki T, Mukai M, Shirakawa A, Shinnou Y, Jinno M, Yanai H, Taguchi K, Maehara Y, Iwamoto Y, Oda Y (2016) Histological spectrum of angiofibroma of soft tissue: histological and genetic analysis of 13 cases. Histopathology 69:459–469. https://doi.org/10.1111/his.12943CrossRefPubMed

10.

Jin Y, Moller E, Nord KH, Mandahl N, Von Steyern FV, Domanski HA, Marino-Enriquez A, Magnusson L, Nilsson J, Sciot R, Fletcher CD, Debiec-Rychter M, Mertens F (2012) Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer 51:510–520. https://doi.org/10.1002/gcc.21939CrossRefPubMed

11.

Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS (2015) Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud 1:a000471. https://doi.org/10.1101/mcs.a000471CrossRefPubMedPubMedCentral

12.

Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, Gomez-Fernandez CR, Manoj N, Haimes JD, Stahl JA, Dela Cruz FS, Tannenbaum-Dvir S, Glade-Bender JL, Kung AL, DuBois SG, Kozakewich HP, Janeway KA, Perez-Atayde AR, Harris MH (2018) Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 31:463–473. https://doi.org/10.1038/modpathol.2017.127CrossRefPubMed

13.

Bender J, Anderson B, Bloom DA, Rabah R, McDougall R, Vats P, Mody R (2019) Refractory and metastatic infantile fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable response to crizotinib. Cold Spring Harb Mol Case Stud 5. https://doi.org/10.1101/mcs.a003376

14.

Kao YC, Fletcher CDM, Alaggio R, Wexler L, Zhang L, Sung YS, Orhan D, Chang WC, Swanson D, Dickson BC, Antonescu CR (2018) Recurrent BRAF gene fusions in a subset of pediatric spindle cell sarcomas: expanding the genetic spectrum of tumors with overlapping features with infantile fibrosarcoma. Am J Surg Pathol 42:28–38. https://doi.org/10.1097/PAS.0000000000000938CrossRefPubMedPubMedCentral

15.

Wegert J, Vokuhl C, Collord G, Del Castillo V-HM, Farndon SJ, Guzzo C, Jorgensen M, Anderson J, Slater O, Duncan C, Bausenwein S, Streitenberger H, Ziegler B, Furtwangler R, Graf N, Stratton MR, Campbell PJ, Jones DT, Koelsche C, Pfister SM, Mifsud W, Sebire N, Sparber-Sauer M, Koscielniak E, Rosenwald A, Gessler M, Behjati S (2018) Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun 9:2378. https://doi.org/10.1038/s41467-018-04650-6CrossRefPubMedPubMedCentral

16.

Suurmeijer AJH, Dickson BC, Swanson D, Zhang L, Sung YS, Cotzia P, Fletcher CDM, Antonescu CR (2018) A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 57:611–621. https://doi.org/10.1002/gcc.22671CrossRefPubMedPubMedCentral

17.

Agaram NP, Zhang L, Sung YS, Chen CL, Chung CT, Antonescu CR, Fletcher CD (2016) Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. Am J Surg Pathol 40:1407–1416. https://doi.org/10.1097/PAS.0000000000000675CrossRefPubMedPubMedCentral

18.

Yamazaki F, Nakatani F, Asano N, Wakai S, Sekimizu M, Mitani S, Kubo T, Kawai A, Ichikawa H, Yoshida A (2019) Novel NTRK3 fusions in fibrosarcomas of adults. Am J Surg Pathol 43:523–530. https://doi.org/10.1097/PAS.0000000000001194CrossRefPubMed

19.

Croce S, Hostein I, Longacre TA, Mills AM, Perot G, Devouassoux-Shisheboran M, Velasco V, Floquet A, Guyon F, Chakiba C, Querleu D, Khalifa E, Mayeur L, Rebier F, Leguellec S, Soubeyran I, McCluggage WG (2019) Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Mod Pathol. 32:1008–1022. https://doi.org/10.1038/s41379-018-0184-6CrossRefPubMed

20.

Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR (2018) NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am J Surg Pathol 42:791–798. https://doi.org/10.1097/PAS.0000000000001055CrossRefPubMedPubMedCentral

21.

Haller F, Knopf J, Ackermann A, Bieg M, Kleinheinz K, Schlesner M, Moskalev EA, Will R, Satir AA, Abdelmagid IE, Giedl J, Carbon R, Rompel O, Hartmann A, Wiemann S, Metzler M, Agaimy A (2016) Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol 238:700–710. https://doi.org/10.1002/path.4701CrossRefPubMed

22.

Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA (2017) Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 41:1547–1551. https://doi.org/10.1097/PAS.0000000000000911CrossRefPubMedPubMedCentral

23.

Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL (2018) Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol 42:927–935. https://doi.org/10.1097/PAS.0000000000001062CrossRefPubMed

24.

Hung YP, Fletcher CDM, Hornick JL (2018) Evaluation of pan-Trk immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology 73:634–644. https://doi.org/10.1111/his.13666CrossRefPubMed

25.

DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS (2018) The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer 124:4241–4247. https://doi.org/10.1002/cncr.31701CrossRefPubMed

26.

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS (2018) Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 19:705–714. https://doi.org/10.1016/S1470-2045(18)30119-0CrossRefPubMedPubMedCentral

27.

Montgomery EA, Devaney KO, Giordano TJ, Weiss SW (1998) Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin’s disease, and various sarcomas. Mod Pathol 11:384–391PubMed

28.

Boland JM, Folpe AL (2017) Hemosiderotic fibrolipomatous tumor, pleomorphic hyalinizing angiectatic tumor, and myxoinflammatory fibroblastic sarcoma: related or not? Adv Anat Pathol 24:268–277. https://doi.org/10.1097/PAP.0000000000000151CrossRefPubMed

29.

Hallor KH, Sciot R, Staaf J, Heidenblad M, Rydholm A, Bauer HC, Astrom K, Domanski HA, Meis JM, Kindblom LG, Panagopoulos I, Mandahl N, Mertens F (2009) Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol 217:716–727. https://doi.org/10.1002/path.2513CrossRefPubMed

30.

Liu H, Sukov WR, Ro JY (2019) The t(1;10)(p22;q24) TGFBR3/MGEA5 translocation in pleomorphic hyalinizing angiectatic tumor, myxoinflammatory fibroblastic sarcoma, and hemosiderotic fibrolipomatous tumor. Arch Pathol Lab Med 143:212–221. https://doi.org/10.5858/arpa.2017-0412-RACrossRefPubMed

31.

Antonescu CR, Zhang L, Nielsen GP, Rosenberg AE, Dal Cin P, Fletcher CD (2011) Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer 50:757–764. https://doi.org/10.1002/gcc.20897CrossRefPubMedPubMedCentral

32.

Laskin WB, Fetsch JF, Miettinen M (2014) Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome. Am J Surg Pathol 38:1–12. https://doi.org/10.1097/PAS.0b013e31829f3d85CrossRefPubMedPubMedCentral

33.

Carter JM, Sukov WR, Montgomery E, Goldblum JR, Billings SD, Fritchie KJ, Folpe AL (2014) TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms. Am J Surg Pathol 38:1182–1992. https://doi.org/10.1097/PAS.0000000000000212CrossRefPubMed

34.

Michal M, Kazakov DV, Hadravsky L, Agaimy A, Svajdler M, Kuroda N, Michal M (2016) Pleomorphic hyalinizing angiectatic tumor revisited: all tumors manifest typical morphologic features of myxoinflammatory fibroblastic sarcoma, further suggesting 2 morphologic variants of a single entity. Ann Diagn Pathol 20:40–43. https://doi.org/10.1016/j.anndiagpath.2015.10.006CrossRefPubMed

35.

Network CGAR (2017) Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171:950–965 e928CrossRef

36.

Kao YC, Ranucci V, Zhang L, Sung YS, Athanasian EA, Swanson D, Dickson BC, Antonescu CR (2017) Recurrent BRAF gene rearrangements in myxoinflammatory fibroblastic sarcomas, but not hemosiderotic fibrolipomatous tumors. Am J Surg Pathol 41:1456–1465. https://doi.org/10.1097/PAS.0000000000000899CrossRefPubMedPubMedCentral

37.

Guillou L, Benhattar J, Gengler C, Gallagher G, Ranchere-Vince D, Collin F, Terrier P, Terrier-Lacombe MJ, Leroux A, Marques B, Aubain Somerhausen Nde S, Keslair F, Pedeutour F, Coindre JM (2007) Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol 31:1387–1402. https://doi.org/10.1097/PAS.0b013e3180321959CrossRefPubMed

38.

Rekhi B, Deshmukh M, Jambhekar NA (2011) Low-grade fibromyxoid sarcoma: a clinicopathologic study of 18 cases, including histopathologic relationship with sclerosing epithelioid fibrosarcoma in a subset of cases. Ann Diagn Pathol 15:303–311. https://doi.org/10.1016/j.anndiagpath.2011.02.005CrossRefPubMed

39.

Mohamed M, Fisher C, Thway K (2017) Low-grade fibromyxoid sarcoma: Clinical, morphologic and genetic features. Ann Diagn Pathol 28:60–67. https://doi.org/10.1016/j.anndiagpath.2017.04.001CrossRefPubMed

40.

Antonescu CR, Rosenblum MK, Pereira P, Nascimento AG, Woodruff JM (2001) Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol 25:699–709CrossRef

41.

Arbajian E, Puls F, Magnusson L, Thway K, Fisher C, Sumathi VP, Tayebwa J, Nord KH, Kindblom LG, Mertens F (2014) Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol 38:801–808. https://doi.org/10.1097/PAS.0000000000000158CrossRefPubMed

42.

Wang WL, Evans HL, Meis JM, Liegl-Atzwanger B, Bovee JV, Goldblum JR, Billings SD, Rubin BP, Lopez-Terrada D, Lazar AJ (2012) FUS rearrangements are rare in ʻpure’ sclerosing epithelioid fibrosarcoma. Mod Pathol 25:846–853. https://doi.org/10.1038/modpathol.2011.214CrossRefPubMed

43.

Stockman DL, Ali SM, He J, Ross JS, Meis JM (2014) Sclerosing epithelioid fibrosarcoma presenting as intraabdominal sarcomatosis with a novel EWSR1-CREB3L1 gene fusion. Hum Pathol 45:2173–2178. https://doi.org/10.1016/j.humpath.2014.05.006CrossRefPubMed

44.

Lau PP, Lui PC, Lau GT, Yau DT, Cheung ET, Chan JK (2013) EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma. Am J Surg Pathol 37:734–738. https://doi.org/10.1097/PAS.0b013e31827560f8CrossRefPubMed

45.

Dewaele B, Libbrecht L, Levy G, Brichard B, Vanspauwen V, Sciot R, Debiec-Rychter M (2017) A novel EWS-CREB3L3 gene fusion in a mesenteric sclerosing epithelioid fibrosarcoma. Genes Chromosomes Cancer 56:695–699. https://doi.org/10.1002/gcc.22474CrossRefPubMed

46.

Dong F, Quade BJ, Dal Cin P, Jo VY (2018) Expanding the spectrum of translocations in sclerosing epitheloid fibrosarcoma: a new case with EWSR1-CREB3L3 fusion. Genes Chromosomes Cancer 57:675–677. https://doi.org/10.1002/gcc.22677CrossRefPubMed

47.

Arbajian E, Puls F, Antonescu CR, Amary F, Sciot R, Debiec-Rychter M, Sumathi VP, Jaras M, Magnusson L, Nilsson J, Hofvander J, Mertens F (2017) In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. Clin Cancer Res 23:7426–7434. https://doi.org/10.1158/1078-0432.CCR-17-1856CrossRefPubMed

48.

Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM (2013) Identification of recurrent NAB2–STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45:180–185. https://doi.org/10.1038/ng.2509CrossRefPubMedPubMedCentral

49.

Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M (2013) Whole-exome sequencing identifies a recurrent NAB2–STAT6 fusion in solitary fibrous tumors. Nat Genet 45:131–132. https://doi.org/10.1038/ng.2522CrossRefPubMedPubMedCentral

50.

Koelsche C, Schweizer L, Renner M, Warth A, Jones DT, Sahm F, Reuss DE, Capper D, Knosel T, Schulz B, Petersen I, Ulrich A, Renker EK, Lehner B, Pfister SM, Schirmacher P, von Deimling A, Mechtersheimer G (2014) Nuclear relocation of STAT6 reliably predicts NAB2–STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology 65:613–622. https://doi.org/10.1111/his.12431CrossRefPubMed

51.

Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL (2014) Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 27:390–395. https://doi.org/10.1038/modpathol.2013.164CrossRefPubMed

52.

Demicco EG, Harms PW, Patel RM, Smith SC, Ingram D, Torres K, Carskadon SL, Camelo-Piragua S, McHugh JB, Siddiqui J, Palanisamy N, Lucas DR, Lazar AJ, Wang WL (2015) Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol 143:672–682. https://doi.org/10.1309/AJCPN25NJTOUNPNFCrossRefPubMed

53.

Demicco EG, Wani K, Ingram D, Wagner M, Maki RG, Rizzo A, Meeker A, Lazar AJ, Wang WL (2018) TERT promoter mutations in solitary fibrous tumour. Histopathology 73:843–851. https://doi.org/10.1111/his.13703CrossRefPubMed

54.

Lin Y, Seger N, Tsagkozis P, Hesla AC, Ghaderi M, Chen Y, Ehnman M, Warsito D, Wejde J, Larsson O, Haglund F (2018) Telomerase promoter mutations and copy number alterations in solitary fibrous tumours. J Clin Pathol 71:832–839. https://doi.org/10.1136/jclinpath-2018-205132CrossRefPubMed

55.

Akaike K, Kurisaki-Arakawa A, Hara K, Suehara Y, Takagi T, Mitani K, Kaneko K, Yao T, Saito T (2015) Distinct clinicopathological features of NAB2–STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum Pathol 46:347–356. https://doi.org/10.1016/j.humpath.2014.11.018CrossRefPubMed

56.

Bahrami A, Lee S, Schaefer IM, Boland JM, Patton KT, Pounds S, Fletcher CD (2016) TERT promoter mutations and prognosis in solitary fibrous tumor. Mod Pathol 29:1511–1522. https://doi.org/10.1038/modpathol.2016.126CrossRefPubMedPubMedCentral

57.

Barthelmess S, Geddert H, Boltze C, Moskalev EA, Bieg M, Sirbu H, Brors B, Wiemann S, Hartmann A, Agaimy A, Haller F (2014) Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2–STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol 184:1209–1218. https://doi.org/10.1016/j.ajpath.2013.12.016CrossRefPubMed

58.

Tai HC, Chuang IC, Chen TC, Li CF, Huang SC, Kao YC, Lin PC, Tsai JW, Lan J, Yu SC, Yen SL, Jung SM, Liao KC, Fang FM, Huang HY (2015) NAB2–STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors. Mod Pathol 28:1324–1335. https://doi.org/10.1038/modpathol.2015.90CrossRefPubMed

59.

Huang SC, Li CF, Kao YC, Chuang IC, Tai HC, Tsai JW, Yu SC, Huang HY, Lan J, Yen SL, Lin PC, Chen TC (2016) The clinicopathological significance of NAB2–STAT6 gene fusions in 52 cases of intrathoracic solitary fibrous tumors. Cancer Med 5:159–168. https://doi.org/10.1002/cam4.572CrossRefPubMed

60.

Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE, Lazar AJ, Wang WL (2012) Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 25:1298–1306. https://doi.org/10.1038/modpathol.2012.83CrossRefPubMed

61.

Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ, Wang WL (2017) Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod Pathol 30:1433–1442. https://doi.org/10.1038/modpathol.2017.54CrossRefPubMed

62.

Pasquali S, Gronchi A, Strauss D, Bonvalot S, Jeys L, Stacchiotti S, Hayes A, Honore C, Collini P, Renne SL, Alexander N, Grimer RJ, Callegaro D, Sumathi VP, Gourevitch D, Desai A (2016) Resectable extra-pleural and extra-meningeal solitary fibrous tumours: a multi-centre prognostic study. Eur J Surg Oncol 42:1064–1070. https://doi.org/10.1016/j.ejso.2016.01.023CrossRefPubMed

63.

Salas S, Resseguier N, Blay JY, Le Cesne A, Italiano A, Chevreau C, Rosset P, Isambert N, Soulie P, Cupissol D, Delcambre C, Bay JO, Dubray-Longeras P, Krengli M, De Bari B, Villa S, Kaanders J, Torrente S, Pasquier D, Thariat JO, Myroslav L, Sole CV, Dincbas HF, Habboush JY, Zilli T, Dragan T, Khan RK, Ugurluer G, Cena T, Duffaud F, Penel N, Bertucci F, Ranchere-Vince D, Terrier P, Bonvalot S, Macagno N, Lemoine C, Lae M, Coindre JM, Bouvier C (2017) Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol 28:1979–1987. https://doi.org/10.1093/annonc/mdx250CrossRefPubMed

64.

Friis RB, Safwat A, Baad-Hansen T, Aggerholm-Pedersen N (2018) Solitary fibrous tumour: a single institution retrospective study and further validation of a prognostic risk assessment system. Clin Oncol (R Coll Radiol) 30:798–804. https://doi.org/10.1016/j.clon.2018.08.015CrossRef

65.

Demicco EG, Griffin AM, Gladdy RA, Dickson BC, Ferguson PC, Swallow CJ, Wunder JS, Wang WL (2019) Comparison of published risk models to predict outcome in extrameningeal solitary fibrous tumor. Histopathology. https://doi.org/10.1111/his.13940

66.

Lee AY, Agaram NP, Qin LX, Kuk D, Curtin C, Brennan MF, Singer S (2016) Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Ann Surg Oncol 23:818–825. https://doi.org/10.1245/s10434-015-5063-5CrossRefPubMedPubMedCentral

67.

Song B, Lee K, Lee C, Moon KC (2018) Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Pathol Int 68:509–516. https://doi.org/10.1111/pin.12709CrossRefPubMed

68.

Yoo HJ, Hong SH, Kang Y, Choi JY, Moon KC, Kim HS, Han I, Yi M, Kang HS (2014) MR imaging of myxofibrosarcoma and undifferentiated sarcoma with emphasis on tail sign; diagnostic and prognostic value. Eur Radiol 24:1749–1757. https://doi.org/10.1007/s00330-014-3181-2CrossRefPubMed

69.

Lefkowitz RA, Landa J, Hwang S, Zabor EC, Moskowitz CS, Agaram NP, Panicek DM (2013) Myxofibrosarcoma: prevalence and diagnostic value of the “tail sign” on magnetic resonance imaging. Skeletal Radiol 42:809–818. https://doi.org/10.1007/s00256-012-1563-6CrossRefPubMedPubMedCentral

70.

Imanishi J, Slavin J, Pianta M, Jackett L, Ngan SY, Tanaka T, Charoenlap C, Dib C, Choong PF (2016) Tail of superficial myxofibrosarcoma and undifferentiated pleomorphic sarcoma after preoperative radiotherapy. Anticancer Res 36:2339–2344PubMed

71.

Kikuta K, Kubota D, Yoshida A, Morioka H, Toyama Y, Chuuman H, Kawai A (2015) An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. Skeletal Radiol 44:55–62. https://doi.org/10.1007/s00256-014-1992-5CrossRefPubMed

72.

Iwata S, Yonemoto T, Araki A, Ikebe D, Kamoda H, Hagiwara Y, Ishii T (2014) Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol 110:707–711. https://doi.org/10.1002/jso.23708CrossRefPubMed

73.

Sambri A, Spinnato P, Bazzocchi A, Tuzzato GM, Donati D, Bianchi G (2019) Does pre-operative MRI predict the risk of local recurrence in primary myxofibrosarcoma of the extremities? Asia Pac J Clin Oncol. https://doi.org/10.1111/ajco.13161

74.

Morii T, Tajima T, Honya K, Aoyagi T, Ichimura S (2018) Clinical significance of the tail-like pattern in soft-tissue sarcomas on magnetic resonance imaging. J Orthop Sci 23:1032–1037. https://doi.org/10.1016/j.jos.2018.06.010CrossRefPubMed

75.

Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamaguchi T, Hasegawa T, Yamashita T (2008) MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol 37:1085–1090. https://doi.org/10.1007/s00256-008-0542-4CrossRefPubMed

Titel: What’s new in fibroblastic tumors?
verfasst von: Susan M. Armstrong
Elizabeth G. Demicco
Publikationsdatum: 01.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 1/2020
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02682-x

Springer Medizin

What’s new in fibroblastic tumors?

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

What’s new in bone forming tumours of the skeleton?

Ewing sarcoma and Ewing-like tumors

Update on selected advances in the immunohistochemical and molecular genetic analysis of soft tissue tumors

Contemporary approaches to soft tissue and bone pathology

The current landscape of rhabdomyosarcomas: an update

Molecular findings in maxillofacial bone tumours and its diagnostic value

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie